Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Takeda Pharmaceutical Company (TAK)
NYSE:TAK
RESEARCH TOOLSreports
Holding TAK?
Track your performance easily
Earnings Data
Report Date
Jan 30, 2025TBA Not Confirmed
Period Ending
2024 (Q3)Consensus EPS Forecast
0.09Last Year’s EPS
0.23Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2018
|% Change Since: -6.05%
|Next Earnings Date:Jul 31, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a mixed performance with notable achievements in product launches and pipeline progress, offset by challenges from generic competition and profit declines. While growth in new products is promising, the financial impact of loss of exclusivity on core products remains a concern.Company Guidance
During Takeda's fiscal year 2023 third-quarter earnings call, executives provided detailed guidance and discussed several key metrics. The company reported a revenue of JPY 3.2 trillion, reflecting flat growth at constant exchange rates and a 4.6% increase at actual exchange rates. This was driven by a 12.7% growth in its growth and launch products, which now comprise 43% of total revenue. Despite a 12.7% decline in core operating profit at constant exchange rates (9.3% at actual exchange rates), primarily due to the loss of exclusivity on high-margin products like VYVANSE and AZILVA, Takeda remains on track to exceed JPY 1 trillion in core operating profit for the year. The company is optimistic about future revenue, profit, and margin growth driven by its innovative pipeline and strategic R&D investments, with a return to core operating profit margins in the low to mid-30s. Takeda also highlighted its robust pipeline developments, including the approval of two new drugs in the U.S., and continued expansion in markets for existing products like ENTYVIO and Qdenga.Growth in Launch Products
Launch products now represent 43% of total revenue, with a growth of 12.7% at constant exchange rates.
Strong Pipeline Progress
Approval of two new molecular entities, FRUZAQLA for metastatic colorectal cancer and ADZYNMA for congenital thrombocytopenic purpura in the U.S.
ENTYVIO Performance
ENTYVIO outperformed the IBD market with 7% revenue growth and maintained its lead as the most prescribed treatment for IBD in the U.S.
Global Expansion of Qdenga
Qdenga was launched in 21 countries with strong initial demand, including a significant recommendation for inclusion in Brazil's national immunization program.
---
TAK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TAK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $13.89 | $13.94 | +0.36% |
| Jul 31, 2024 | $13.65 | $13.88 | +1.68% |
| May 09, 2024 | $13.06 | $13.37 | +2.37% |
| Feb 01, 2024 | $14.60 | $14.38 | -1.51% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Takeda Pharmaceutical Company (TAK) report earnings?
Takeda Pharmaceutical Company (TAK) is schdueled to report earning on Jan 30, 2025, TBA Not Confirmed.
What is Takeda Pharmaceutical Company (TAK) earnings time?
Takeda Pharmaceutical Company (TAK) earnings time is at Jan 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TAK EPS forecast?
TAK EPS forecast for the fiscal quarter 2024 (Q3) is 0.09.
---